Clark Eliana's Form 4 filing
Intellia Therapeutics, Inc. (NTLA) · filed Jan 6, 2023
- Accession no.
- 0001209191-23-002412
- Filed
- Jan 6, 2023
- Trade date
- Jul 1, 2022-Jan 4, 2023
- Filing delay
- 189 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $76.4K. It was filed 189 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Clark ElianaCIK 0001914448 | Officer (EVP, Chief Technical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2022 | Common Stock | SSaleDisposed | −105 | $51.74 | −$5,432.7 | 16,165 | Direct | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −231 | $34.48 | −$7,964.88 | 16,165 | Direct | |
| Jan 4, 2023 | Common Stock | SSaleDisposed | −1,692 | $37.21 | −$62,959.32 | 14,473 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.